UK first to approve Omicron COVID shot with Moderna nod



* UK's JCVI backs using bivalent shot in autumn booster campaign

* Moderna sees Australia, Canada, EU approvals soon

By Natalie Grover

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

The UK medicines regulator (MHRA) gave the so-called bivalent vaccine made by U.S. drug company Moderna MRNA.O conditional approval as a booster for adults on Monday.

Later on Monday, the UK's Joint Committee on Vaccination and Immunisation (JCVI) backed the use of the variant-adapted shot in the country's booster campaign starting September.

The MHRA's Moderna decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original virus, it said.

Moderna in June said trial data showed that when given as a fourth dose, the variant-adapted shot raised virus-neutralizing antibodies by eight-fold against Omicron.

The MHRA also cited an exploratory analysis in which the shot was found to generate a "good immune response" against the currently dominant Omicron offshoots BA.4 and BA.5.

According to Moderna, trial data showed its variant-adapted booster generated virus-neutralizing antibody levels against the subvariants that were 1.69 times higher than those given the original booster.

However, the correlation between neutralizing antibody levels and vaccine effectiveness against disease - in particular severe disease - remains unclear.

No serious safety concerns were identified with the new Moderna formulation, the MHRA added on Monday.

While existing COVID-19 vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the virus has evolved.

"What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve," MHRA Chief Executive June Raine said in a statement.

However, the virus is unlikely to stand still and Omicron-targeted immunity might push the virus down other evolutionary paths, added Jonathan Ball, professor of molecular virology at the University of Nottingham.

"In which case we will be like the Red Queen in Alice and the Looking Glass - having to keep running just to stay in the same place."

FURTHER APPROVALS

European Medicines Agency (EMA) officials expect COVID variant-adapted vaccines to be approved in the European Union by September, and have signalled the regulator is open to using shots targeting the older BA.1 variant this autumn, given those specifically targeting newer subvariants are further behind in clinical development.

In contrast, the U.S. Food and Drug Administration (FDA) has said it will seek the specific inclusion of the newer BA.4 and BA.5 offshoots of Omicron in any new shots used domestically.

On Monday, the chief of Serum Institute of India - which produces AstraZeneca's COVID-19 vaccine under the brand name Covishield - said he expected an Omicron-specific vaccine in the country in six months, NDTV reported.

Moderna, which signed a 1 billion pound ($1.2 billion) deal with the British government to build the country's first mRNA vaccine facility earlier this year, on Monday said it expected further approvals for the adapted vaccine in Australia, Canada, and the EU in the coming weeks.

Pfizer Inc PFE.N and BioNTech 22UAy.DE have also been testing versions of their mRNA vaccine modified to combat Omicron variants.

($1 = 0.8270 pounds)
Reporting by Natalie Grover in London Editing by David Goodman, Mark Potter and Marguerita Choy

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Nous utilisons des cookies pour vous donner la meilleure expérience possible de notre site internet. En savoir plus ou modifier vos paramètres de cookies.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques